A portfolio of advanced product candidates based on immune activation and regulation in Phase 2 and Phase 3 clinical development, as well as novel preclinical candidates set to enter the development stage

The company’s strategy is based on the development of a balanced product portfolio with a diversified risk profile, and on the development of innovative drug candidates in the areas of immuno-oncology, autoimmune diseases and transplantation. This new generation of products is optimized to better target key receptors of the activation or regulation of immune response and allow a durable therapeutic effet.